science

Niraparib/abiraterone acetate

Niraparib/abiraterone acetate is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Niraparib/abiraterone acetate rather than just read about it. In short: Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).

Key takeaways

Niraparib/abiraterone acetate belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Niraparib/abiraterone acetate to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Niraparib/abiraterone acetate from memory before moving on to harder problems.

Reference excerpt

Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist). The most common side effects include anemia (low levels of red blood cells), high blood pressure, constipation, tiredness, nausea, thrombocytopenia (low levels of blood platelets), difficulty breathing, back pain, reduced appetite, neutropenia (low levels of neutrophils, a type of white blood cell), joint pain, vomiting, low levels of potassium, dizziness, difficulty sleeping, high blood glucose levels, and urinary tract infection. Niraparib/abiraterone acetate was approved for medical use in the European Union in April 2023, and in the United States in August 2023.

Medical uses In the European Union, niraparib/abiraterone is indicated for the treatment of adults with prostate cancer. It is for people who have genetic mutations known as BRCA 1/2 mutations and who cannot have chemotherapy. It is used in combination with prednisolone or another medicine prednisone, which is converted into prednisolone. In the United States, niraparib/abiraterone is indicated, in combination with prednisone, for adults with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer, as determined by an FDA-approved test.

History Efficacy was evaluated in cohort 1 of MAGNITUDE (NCT03748641), a randomized, double-blind, placebo-controlled trial enrolling 423 participants with homologous recombination repair (HRR) gene-mutated mCRPC. Participants were randomized (1:1) to receive niraparib 200 mg and abiraterone acetate 1,000 mg plus prednisone 10 mg daily or placebo and abiraterone acetate plus prednisone daily. Participants were required to have a prior orchiectomy or be receiving gonadotropin-releasing hormone (GnRH) analogues. Participants with mCRPC were eligible if they had not received prior systemic therapy in the mCRPC setting except for a short duration of prior abiraterone acetate plus prednisone (up to four months) and ongoing ADT. Participants could have received prior docetaxel or androgen-receptor (AR) targeted therapies in earlier disease settings. Randomization was stratified by prior docetaxel, prior AR targeted therapy, prior abiraterone acetate plus prednisone, and BRCA status. Of the 423 participants enrolled, 225 (53%) had prospectively determined BRCA gene mutations (BRCAm). No benefit was observed in mCRPC participants without an HRR gene mutation (Cohort 2 of MAGNITUDE) as the criterion for futility was met.

Society and culture

Legal status On 23 February 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Akeega, intended for the treatment of adults with metastatic castration-resistant prostate cancer with BRCA 1/BRCA 2 mutations. The applicant for this medicinal product is Janssen-Cilag International N.V. Niraparib/abiraterone acetate was approved for medical use in the European Union in April 2023. It was approved for use in the United States in August 2023, based on the Phase 3 MAGNITUDE study.

References

Worked examples

Example 1 — a first encounter with Niraparib/abiraterone acetate

Start with the simplest possible case. Write down what Niraparib/abiraterone acetate claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Niraparib/abiraterone acetate before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Niraparib/abiraterone acetate ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Niraparib/abiraterone acetate

In research: Niraparib/abiraterone acetate appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Niraparib/abiraterone acetate in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Niraparib/abiraterone acetate is common in secondary-school and first-year university syllabi. It links to neighbouring topics CYP17A1 inhibitors, Cancer treatments, Combination cancer drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Niraparib/abiraterone acetate outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Niraparib/abiraterone acetate” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Niraparib/abiraterone acetate in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Niraparib/abiraterone acetate means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Niraparib/abiraterone acetate out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Niraparib/abiraterone acetate in simple terms?

Why does Niraparib/abiraterone acetate matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Niraparib/abiraterone acetate?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Niraparib/abiraterone acetate.